Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,506.48
(
-1.51%
)
US TECH 100
23,344.00
(
-1.59%
)
Dow Jones
45,577.47
(
-0.96%
)
Brent Oil
108.44
(
3.84%
)
Bitcoin
70,464.00
(
0.81%
)
News Focus
News Focus
Post# of 257264
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122806
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 36527

Monday, 10/30/2006 1:49:03 PM

Monday, October 30, 2006 1:49:03 PM

Post# of 257264
EMIS post-mortem:

One reason I’m interested in EMIS’ oral-insulin data is to see whether portal delivery of insulin is really an advantage vs systemic delivery, as EMIS and at least one other company have asserted. Alas, the data released today are too sketchy to say much of anything on this score.

It’s simply preposterous, IMO, that EMIS labeled the mean HbA1c reduction in each trial arm as supplementary data to be released after further study rather than top-line data to be released immediately.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today